IN VIVO
Scope & Guideline
Unveiling the complexities of life sciences for a healthier tomorrow.
Introduction
Aims and Scopes
- Translational Medicine:
Research that connects laboratory findings with clinical applications, aiming to enhance patient care and treatment outcomes. - Oncology and Cancer Research:
A significant focus on various aspects of cancer research, including novel treatment modalities, prognostic factors, and molecular mechanisms underlying tumorigenesis. - Pharmacology and Drug Development:
Studies exploring drug efficacy, mechanisms of action, and the impact of pharmacogenomics on treatment responses. - Regenerative Medicine and Tissue Engineering:
Research involving stem cells, tissue scaffolds, and regenerative therapies to repair or replace damaged tissues. - Immunology and Inflammatory Diseases:
Investigations into immune responses, inflammation processes, and their implications in various diseases, particularly cancer and autoimmune conditions. - Surgical Techniques and Outcomes:
Evaluation of surgical interventions, including innovative surgical techniques, their effectiveness, and patient outcomes. - Biomarkers and Diagnostic Tools:
Research aimed at identifying novel biomarkers for disease diagnosis, prognosis, and monitoring therapeutic responses.
Trending and Emerging
- Precision Medicine and Personalized Therapies:
Research focused on tailoring treatments to individual patient characteristics, including genetic profiling and targeted therapies, is gaining momentum. - Immunotherapy and Cancer Vaccines:
An increase in studies exploring the efficacy and mechanisms of immunotherapy and novel cancer vaccines, reflecting the growing importance of these approaches in oncology. - Regenerative Medicine Innovations:
Emerging techniques in regenerative medicine, including the application of stem cells and biomaterials for tissue repair, are becoming more prevalent. - Artificial Intelligence in Medical Research:
The integration of artificial intelligence and machine learning in analyzing research data, predicting outcomes, and improving diagnostic accuracy is on the rise. - Longitudinal Studies on Treatment Outcomes:
A trend towards conducting long-term studies that assess the outcomes of various treatment modalities in cancer and other chronic diseases. - Microbiome Research:
Increasing interest in the role of the microbiome in health, disease progression, and treatment efficacy, particularly in cancer therapy.
Declining or Waning
- Basic Science Research:
There seems to be a decline in purely basic science studies that do not translate into clinical applications, as the journal increasingly prioritizes research with direct clinical relevance. - Animal Models of Non-Oncological Diseases:
Research focusing on animal models for diseases other than cancer appears less frequent, possibly due to a greater emphasis on cancer-related studies and translational impacts. - Epidemiological Studies:
Epidemiological research that does not directly tie into clinical interventions or outcomes has seen reduced representation, suggesting a shift towards more intervention-focused studies. - Traditional Diagnostic Methods:
There is a noticeable decrease in studies focusing on conventional diagnostic methods, as the journal shifts towards innovative techniques and biomarkers.
Similar Journals
Immuno
Advancing Immunology Through Open Access InnovationWelcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.
Biomed Research International
Exploring the frontiers of biomedicine for a healthier future.Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.
Molecular and Clinical Oncology
Exploring new frontiers in molecular and clinical oncology.Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.
EXPERIMENTAL AND MOLECULAR MEDICINE
Connecting scholars to the latest in experimental medicine.EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.
M S-MEDECINE SCIENCES
Exploring the nexus of genetics and innovative healthcare.M S-MEDECINE SCIENCES, published by EDP SCIENCES S A, is an esteemed journal based in France dedicated to the fields of biochemistry, genetics, and medicine. With an ISSN of 0767-0974 and an E-ISSN of 1958-5381, this journal has been a platform for scholarly communication since its inception in 1990 and continues to present critical advancements in these scientific domains, aiming to bridge theoretical research with practical applications. Despite its current Q4 ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories, the journal aspires to enhance its visibility and impact within the academic community. Researchers and professionals can benefit from a wealth of studies that contribute to the understanding of complex biological systems and medical innovations. Interested authors are encouraged to explore the journal's submission guidelines and contribute to the growing body of knowledge in these important fields.
International Journal of Biomedicine
Driving innovation in genetics, immunology, and beyond.International Journal of Biomedicine, published by INT MEDICAL RESEARCH & DEVELOPMENT CORP, is a premier Open Access journal dedicated to advancing knowledge in the multifaceted fields of biomedicine, including but not limited to biochemistry, genetics, immunology, microbiology, and neuroscience. With its ISSN 2158-0510 and E-ISSN 2158-0529, this journal has been serving as a significant platform for researchers since its inception in 2011, ensuring the dissemination of high-quality, peer-reviewed articles. Despite currently holding a Q4 ranking in prominent categories such as Biochemistry, Genetics and Molecular Biology and Neuroscience, the journal plays a vital role in fostering scientific dialogue and innovation in these rapidly evolving domains. The journal's commitment to accessibility further empowers both seasoned professionals and budding scholars to contribute to, and benefit from, the wealth of research that characterizes the biomedicine landscape. With a significant emphasis on interdisciplinary approaches and contemporary issues, the International Journal of Biomedicine is an essential resource for those aiming to navigate the complex intersections of health, disease, and biomedical discovery.
MedComm
Unleashing Potential in Drug Discovery and GeneticsMedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.
FASEB BioAdvances
Transforming Insights into Impactful ResearchFASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.
Biochemistry Moscow-Supplement Series B-Biomedical Chemistry
Unveiling the Secrets of Life Through Cutting-Edge Biochemical Research.Biochemistry Moscow-Supplement Series B-Biomedical Chemistry, published by MAIK NAUKA-INTERPERIODICA, is a pivotal journal in the fields of biochemistry, clinical biochemistry, and molecular medicine. Established in 2008, the journal serves as a vital platform for researchers and professionals seeking to disseminate and access groundbreaking research in the biomedical sciences. With an ISSN of 1990-7508 and an E-ISSN of 1990-7516, the journal has been recognized in the Q4 quartile across various categories as of 2023, highlighting its emerging presence in the academic community despite a competitive landscape. Although currently not available as Open Access, the journal encompasses a broad spectrum of studies, ranging from theoretical analysis to practical applications in biomedical research. The journal's dedicated focus on advancing our understanding of biochemical principles positions it as an essential resource for students and professionals alike, enhancing its significance in the global scientific dialogue.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Pioneering Discoveries in Diagnostic and Therapeutic StrategiesINTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.